128 related articles for article (PubMed ID: 36254608)
1. Association between
Fan Z; Chen R; Li M; Gu J; Li X; Wei W
Expert Rev Mol Diagn; 2022 Sep; 22(9):895-903. PubMed ID: 36254608
[TBL] [Abstract][Full Text] [Related]
2. Role of CDH1 promoter polymorphism and DNA methylation in bladder carcinogenesis: a meta-analysis.
Wang Y; Kong CZ; Zhang Z; Yang CM; Li J
DNA Cell Biol; 2014 Apr; 33(4):205-16. PubMed ID: 24491043
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological significance and potential drug targeting of CDH1 in lung cancer: a meta-analysis and literature review.
Yu Q; Guo Q; Chen L; Liu S
Drug Des Devel Ther; 2015; 9():2171-8. PubMed ID: 25931811
[TBL] [Abstract][Full Text] [Related]
4. The association between CDH1 promoter methylation and patients with ovarian cancer: a systematic meta-analysis.
Wang Q; Wang B; Zhang YM; Wang W
J Ovarian Res; 2016 Apr; 9():23. PubMed ID: 27067410
[TBL] [Abstract][Full Text] [Related]
5. Role of CDH1 promoter methylation in colorectal carcinogenesis: a meta-analysis.
Li YX; Lu Y; Li CY; Yuan P; Lin SS
DNA Cell Biol; 2014 Jul; 33(7):455-62. PubMed ID: 24684676
[TBL] [Abstract][Full Text] [Related]
6. Association of genetic variants in and promoter hypermethylation of CDH1 with gastric cancer: a meta-analysis.
Jing H; Dai F; Zhao C; Yang J; Li L; Kota P; Mao L; Xiang K; Zheng C; Yang J
Medicine (Baltimore); 2014 Oct; 93(19):e107. PubMed ID: 25340495
[TBL] [Abstract][Full Text] [Related]
7. Associations of RASSF1A, RARβ, and CDH1 promoter hypermethylation with oral cancer risk: A PRISMA-compliant meta-analysis.
Wen G; Wang H; Zhong Z
Medicine (Baltimore); 2018 Mar; 97(11):e9971. PubMed ID: 29538221
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review.
Huang R; Ding P; Yang F
Drug Des Devel Ther; 2015; 9():5277-85. PubMed ID: 26425077
[TBL] [Abstract][Full Text] [Related]
9. E-cadherin (CDH1) gene -160C/A polymorphism and the risk of colorectal cancer: A meta-analysis involving 17,291 subjects.
Ye CC; Wang J
J Gene Med; 2021 Oct; 23(10):e3370. PubMed ID: 34097324
[TBL] [Abstract][Full Text] [Related]
10. The clinicopathological significance of CDH1 in gastric cancer: a meta-analysis and systematic review.
Zeng W; Zhu J; Shan L; Han Z; Aerxiding P; Quhai A; Zeng F; Wang Z; Li H
Drug Des Devel Ther; 2015; 9():2149-57. PubMed ID: 25926721
[TBL] [Abstract][Full Text] [Related]
11. Loss of expression and aberrant methylation of the CDH1 (E-cadherin) gene in breast cancer patients from Kashmir.
Asiaf A; Ahmad ST; Aziz SA; Malik AA; Rasool Z; Masood A; Zargar MA
Asian Pac J Cancer Prev; 2014; 15(15):6397-403. PubMed ID: 25124632
[TBL] [Abstract][Full Text] [Related]
12. Abnormal MGMT promoter methylation may contribute to the risk of esophageal cancer: a meta-analysis of cohort studies.
Zhao JJ; Li HY; Wang D; Yao H; Sun DW
Tumour Biol; 2014 Oct; 35(10):10085-93. PubMed ID: 25015189
[TBL] [Abstract][Full Text] [Related]
13. The association, clinicopathological significance, and diagnostic value of
Shen Z; Zhou C; Li J; Deng H; Li Q; Wang J
Onco Targets Ther; 2016; 9():6763-6773. PubMed ID: 27826202
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of CDH1 and CDH13 DNA-methylation in serum of cervical cancer patients.
Abudukadeer A; Bakry R; Goebel G; Mutz-Dehbalaie I; Widschwendter A; Bonn GK; Fiegl H
Int J Mol Sci; 2012; 13(7):8353-8363. PubMed ID: 22942707
[TBL] [Abstract][Full Text] [Related]
15. Hypermethylation-modulated down-regulation of CDH1 expression contributes to the progression of esophageal cancer.
Ling ZQ; Li P; Ge MH; Zhao X; Hu FJ; Fang XH; Dong ZM; Mao WM
Int J Mol Med; 2011 May; 27(5):625-35. PubMed ID: 21373750
[TBL] [Abstract][Full Text] [Related]
16. Aberrant Methylation of T-cadherin Can Be a Diagnostic Biomarker for Colorectal Cancer.
Duan BS; Xie LF; Wang Y
Cancer Genomics Proteomics; 2017; 14(4):277-284. PubMed ID: 28647701
[TBL] [Abstract][Full Text] [Related]
17. Association between the Epithelial Cadherin - 160C/A Polymorphism and Colorectal Cancer Risk: Evidence from a Meta-Analysis.
Sun N; Chen J; Hu G; Chen X; Jiang J; Zhang L; Wu H
Crit Rev Eukaryot Gene Expr; 2017; 27(4):347-354. PubMed ID: 29283329
[TBL] [Abstract][Full Text] [Related]
18. CDKN2A methylation in esophageal cancer: a meta-analysis.
Zhou C; Li J; Li Q
Oncotarget; 2017 Jul; 8(30):50071-50083. PubMed ID: 28637022
[TBL] [Abstract][Full Text] [Related]
19. A Systematic Analysis of the Relationship of CDH13 Promoter Methylation and Breast Cancer Risk and Prognosis.
Yang J; Niu H; Huang Y; Yang K
PLoS One; 2016; 11(5):e0149185. PubMed ID: 27153114
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological significance of matrix metalloproteinase-7 protein expression in esophageal cancer: a meta-analysis.
Miao S; Zhou SY; Han CS; Zhang LN; Sun HB; Yang B
Drug Des Devel Ther; 2015; 9():3729-40. PubMed ID: 26229436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
